Crinetics Soars 73% As Lead Asset Succeeds in Phase 3 Trial for Acromegaly
$Crinetics Pharmaceuticals(CRNX)$ added 73.89% pre-market Monday after announcing that its lead candidate, paltusotine, achieved the primary endpoint and all secondary endpoints in a Phase 3 trial for
Pre-Bell | Nasdaq Futures Jump 118 Points; Tesla Rises More Than 6%; Apple is up 1.35% Before Big Event
Wall Street futures gained on Monday as Tesla shares rose, while investors awaited inflation data due later this week for clues on the U.S. Federal Reserve's interest-rate path.Market SnapshotAt 8:20